EP1520588A3

Uses of antibodies to aminophospholipids for cancer treatment

Abstract

Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression in vivo. This invention therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach.

Term

Term ended

Projected expiry passed 12 July 2019, 7.2 years ago.

Every citation, both ways

Citations
Document	Relation	Office	Category	Cited during	Relevant claims
WO9601653A1	Cites	World Intellectual Property Organization (WIPO)	A	Search report	1-52
FISHMAN, P. ET AL: "Autoimmunity and cancer - beneficial relationships: A new concept for the production of human monoclonal antibodies", INT. J. ONCOL., ISSN: 1019-6439., vol. 10, no. 5, May 1997 (1997-05-01), pages 901 - 904, XP000867200	Non-patent	–	–	Search report	–
TOBELEM G: "[Antiphospholipid antibodies: specificity and mechanism of action]. Les anticorps antiphospholipides: specificite et mecanisme d'action.", ANNALES DE MEDECINE INTERNE, REF: 30, vol. 141, no. 3, 1990, pages 257 - 260, XP000867067	Non-patent	–	–	Search report	–
FERRO D ET AL: "Coexistence of anti - phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state.", CIRCULATION, vol. 95, no. 6, 18 March 1997 (1997-03-18), pages 1425 - 1432, XP000867066	Non-patent	–	–	Search report	–
THORPE P ET AL: "TUMOR INFARCTION: IMMUNOCONJUGATES THAT COAGULATE THE VASCULATURE OF SOLID TUMORS", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH,US,PHILADELPHIA, AACR, vol. MEETING 86, March 1995 (1995-03-01), pages 488, XP002071589, ISSN: 0197-016X	Non-patent	–	–	Search report	–

46 members in 16 offices; this record represents the family

This recordMember, by publication datePriority claim6 more offices are in the list below

Priority claims5

Priority claims
Document	Office	Kind	Date
92672P	United States of America	–	1998-07-13
9267298	United States of America	P	1998-07-13
110608P	United States of America	–	1998-12-02
11060898	United States of America	P	1998-12-02
99940802	European Patent Office (EPO)	A	1999-07-12

Members46

Family members, oldest first
Document	Office	Kind
CA2333147A1	Canada	A1	2000-01-20
WO0002584A2	World Intellectual Property Organization (WIPO)	A2	2000-01-20
AU5458599A	Australia	A	2000-02-01
WO0002584A3	World Intellectual Property Organization (WIPO)	A3	2000-03-30
EP1096955A2	European Patent Office (EPO)	A2	2001-05-09
IL140701D0	Israel	D0	2002-02-10
HK1039050A1	Hong Kong, China	A1	2002-04-12
US6406693B1	United States of America	B1	2002-06-18
JP2002520295A	Japan	A	2002-07-09
US2003082187A1	United States of America	A1	2003-05-01
NZ508950A	New Zealand	A	2003-10-31
AU771224B2	Australia	B2	2004-03-18
AU2004202605A1	Australia	A1	2004-07-08
EP1096955B1	European Patent Office (EPO)	B1	2004-09-22
AT276763T	Austria	T	2004-10-15
ATE276763T1	Austria	T1	2004-10-15
DE69920462D1	Germany	D1	2004-10-28
BR9911882A	Brazil	A	2005-02-15
EP1520588A2	European Patent Office (EPO)	A2	2005-04-06
ES2233065T3	Spain	T3	2005-06-01
DE69920462T2	Germany	T2	2005-10-13
EP1520588A3This record	European Patent Office (EPO)	A3	2005-12-14
HK1074003A1	Hong Kong, China	A1	2005-12-16
US2006141545A1	United States of America	A1	2006-06-29
EP1096955B9	European Patent Office (EPO)	B9	2006-07-05
JP2006213734A	Japan	A	2006-08-17
AU2004202605B2	Australia	B2	2007-10-25
AU2008200125A1	Australia	A1	2008-01-31
IL140701A	Israel	A	2008-06-05
US7422738B2	United States of America	B2	2008-09-09
JP2011037900A	Japan	A	2011-02-24
EP2311490A2	European Patent Office (EPO)	A2	2011-04-20
EP2311490A3	European Patent Office (EPO)	A3	2011-05-04
JP4743672B2	Japan	B2	2011-08-10
CA2333147C	Canada	C	2012-02-07
US8486391B2	United States of America	B2	2013-07-16
JP2013177445A	Japan	A	2013-09-09
US2014065148A1	United States of America	A1	2014-03-06
US2014322134A1	United States of America	A1	2014-10-30
EP1520588B1	European Patent Office (EPO)	B1	2014-12-24
DK1520588T3	Denmark	T3	2015-03-23
JP5689658B2	Japan	B2	2015-03-25
PT1520588E	Portugal	E	2015-03-31
ES2533255T3	Spain	T3	2015-04-08
CY1116124T1	Cyprus	T1	2017-02-08
US9795673B2	United States of America	B2	2017-10-24

99 legal events, as 15 offices reported them to INPADOC

Over the term

Point at a mark for the event

Events

Legal events, newest first
	Event	Code	Office
2019-10-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-10-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-09-17	Announcement of lapse in spainLapsedFD2A	FD2A	ES
2019-07-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-07-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-05-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-05-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-05-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-05-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-05-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-04-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-04-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-04-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-04-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-04-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-04-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-04-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-04-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-04-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-04-17	Patent lapsedLapsedMM4A	MM4A	IE
2019-04-01	Translation for ep filed (entry of ep into country)FP	FP	BE
2019-04-01	Lapsed because of non-payment of the annual feeLapsedMM	MM	BE
2019-03-29	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-03-29	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-03-27	Gb: european patent ceased through non-payment of renewal feeCeasedGBPC	GBPC	EP
2019-03-15	Lapse because of not paying annual feesLapsedMM01	MM01	AT
2019-03-06	Lapsed because of non-payment of the annual feeLapsedMM	MM	NL
2019-02-28	Patent ceasedCeasedPL	PL	CH
2019-02-25	Ep patent lapsedLapsedEBP	EBP	DK
2019-02-01	Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal feeWithdrawnR119	R119	DE
2017-11-30	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2017-11-30	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2017-11-30	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2017-10-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2017-10-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2017-10-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2017-10-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2017-10-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2017-10-13	Change of the address of the representativeNEW ADDRESS: RUE DU CENDRIER 15 CP 1489, 1201 GENEVE (CH)PCAR	PCAR	CH
2017-09-29	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2017-08-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2017-08-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2017-08-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2017-07-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2017-07-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2017-07-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2017-07-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2017-07-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2017-07-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2017-06-21	Fee paymentPLFP	PLFP	FR
2016-06-21	Fee paymentPLFP	PLFP	FR
2016-02-15	Publication of translation of european patent specificationUEP	UEP	AT
2016-01-15	Name/firm changedPFA	PFA	CH
2015-12-02	No opposition filedOpposition26N	26N	EP
2015-11-03	No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE	PLBE	EP
2015-11-03	Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA	STAA	EP
2015-09-25	No opposition filed against granted patent, or epo opposition proceedings concluded without decisionGrantedR097	R097	DE
2015-07-17	Standard patents granted in hong kongGrantedGR	GR	HK
2015-05-26	Ep patent validated in greeceEP	EP	GR
2015-04-08	Definitive protectionFG2A	FG2A	ES
2015-03-31	Translation is availableAVAILABILITY OF NATIONAL TRANSLATIONSC4A	SC4A	PT
2015-03-31	Translation of granted ep patentGrantedTRGR	TRGR	SE
2015-03-23	Ep patent with danish claimsT3	T3	DK
2015-03-11	Translation files for an european patent granted for nl, confirming art. 52 par. 1 or 6 of the patents act 1995GrantedT3	T3	NL
2015-02-27	New agentNV	NV	CH
2015-02-19	Dpma publication of mentioned ep patent grantGrantedR096	R096	DE
2015-01-15	Reference to at number (ep patent enters austrian national phase)REF	REF	AT
2015-01-14	European patents granted designating irelandGrantedFG4D	FG4D	IE
2014-12-31	European patent takes effect as a national patent in ch/liEP	EP	CH
2014-12-31	CorrectionERGAENZUNG LIZENZEINTRAG: AUSSCHLIESSLICHE LIZENZPK	PK	CH
2014-12-24	Licence recorded111L	111L	EP
2014-12-24	Divisional application: reference to earlier applicationAC	AC	EP
2014-12-24	Designated contracting statesAK	AK	EP
2014-12-24	European patent grantedGrantedFG4D	FG4D	GB
2014-12-03	Intention to grant announcedINTG	INTG	EP
2014-11-28	(expected) grantORIGINAL CODE: 0009210GRAA	GRAA	EP
2014-11-18	Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS	GRAS	EP
2014-11-03	Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP	GRAP	EP
2014-02-01	Appeal procedure closedAppealORIGINAL CODE: EPIDOSNNOA9EAPBT	APBT	EP
2012-08-10	Appeal reference modifiedAppealORIGINAL CODE: EPIDOSCREFNEAPAF	APAF	EP
2012-07-25	Date of receipt of statement of grounds of appeal recordedAppealORIGINAL CODE: EPIDOSNNOA3EAPBR	APBR	EP
2012-05-23	Appeal reference recordedAppealORIGINAL CODE: EPIDOSNREFNEAPBK	APBK	EP
2012-05-23	Date of receipt of notice of appeal recordedAppealORIGINAL CODE: EPIDOSNNOA2EAPBN	APBN	EP
2006-12-06	Licence recorded0100 PEREGRINE PHARMACEUTICALS, INC.111L	111L	EP
2006-08-23	First examination report despatched17Q	17Q	EP
2006-08-23	Designation fees paidAKX	AKX	EP
2005-12-16	Requests to designate patent in hong kongDE	DE	HK
2005-12-14	Designated contracting statesAK	AK	EP
2005-12-14	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2005-12-14	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2005-12-14	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2005-12-14	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2005-12-14	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2005-12-14	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2005-10-28	Search report despatchedORIGINAL CODE: 0009013PUAL	PUAL	EP
2005-04-06	Request for examination filed17P	17P	EP
2005-04-06	Divisional application: reference to earlier applicationAC	AC	EP
2005-04-06	Designated contracting statesAK	AK	EP
2005-02-18	Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI	PUAI	EP

Uses of antibodies to aminophospholipids for cancer treatment

Abstract

Term

Priority claims5

Members46

Over the term

Events

Numbers

Titles3

Classification

Designated states19